You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminopiperidines as novel anti influenza agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDInfluenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission
SBC: EDEN PARK ILLUMINATION, INC. Topic: NIAIDDESCRIPTION provided by applicant Drug resistant bacteria such as MRSA and airborne transmitted microbes such as influenza and TB together present major health issues both in the developed and the developing world with major health care and economic consequences Recent research from Columbia University Medical Center demonstrated that single wavelength far UVC photons can kill bacteria a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A chimeric protein for the selective expansion of regulatory T cells
SBC: SAHANE BIOTECH INC Topic: NIAIDDESCRIPTION provided by applicant Type diabetes T D is a chronic disease caused by the autoimmune destruction of the insulin producing beta cells in the pancreas Current treatment options for T D are severely limited All patients diagnosed with T DM are placed on life long insulin therapy and the current standard of care for adult patients with T DM is intensive diabetes therapy to avoid ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing a method to increase HIV testing among YMSM
SBC: RESILIENT GAMES STUDIO, LLC Topic: NICHDDESCRIPTION provided by applicant Adolescents are particularly vulnerable to HIV and account for one quarter of all new infections each year Most new infections among adolescents occur among young men who have sex with men YMSM Transmission of HIV can be virtually eliminated by treatment but testing rates are low and a significant proportion of YMSM are unaware of their HIV status P ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression
SBC: Norfolk Medical Products, INC. Topic: NIDDKDESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel therapies for inherited muscle diseases
SBC: Medosome Biotec, LLC Topic: NIAMSDESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminomethyl benzamides as novel anti Ebola agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDEbola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development
SBC: QRKANSWER LLC Topic: NCIDESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health